9/25/2023 0 Comments Keynote 811 protocol![]() ![]() However, histological classifications alone are insufficient to effectively stratify patients for individualized treatment and improve patients’ clinical outcomes. Intratumoral and intertumoral heterogeneity are the prominent features of GC that partly contribute to its poor prognosis. Systemic chemotherapy is the mainstay treatment for metastatic GC (mGC), with a median overall survival (OS) of ~ 12 months for patients treated with conventional chemotherapy. ĭespite the high incidence of GC, most patients are unfortunately diagnosed at advanced stages with dismal prognoses due to the lack of distinguishing clinical indications. Aside from Helicobacter Pylori infection, the occurrence of GC has been linked to genetic risk factors as well as lifestyle factors, such as alcohol consumption and smoking. Notably, the incidence of gastric cancer among young adults (aged < 50 years) in recent years has been progressively rising in both low-risk and high-risk countries. The incidence varies geographically across the globe, with the highest incidence in Eastern Asia (Japan and Mongolia) and Eastern Europe, whereas incidence rates in Northern Europe and Northern America are generally low, comparable to African regions. Gastric cancer (GC) is the fifth most common malignant tumor and the fourth leading cause of cancer-associated death worldwide. This review systematically summarizes the main research progress in systemic treatment for GC, discusses current individualized strategies and presents future perspectives. ![]() Molecular diagnostic techniques have facilitated the characterization of GC genetic profiles and the identification of new potential molecular targets. Classification based on molecular biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), provides an opportunity to differentiate patients who may benefit from immunotherapy or targeted therapy. For metastatic disease, there have been notable advancements in immunotherapy and biomarker-directed therapies recently. Ongoing investigations are exploring the potential benefits of targeted therapy or immunotherapy in the perioperative or adjuvant setting. For resectable GC, perioperative chemotherapy has become the standard treatment. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Gastric cancer (GC) is one of the most common malignancies worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |